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Abstract: Nanoscaled devices have great potential for drug delivery applications due to their 
small size. In the present study, we report for the first time the preparation and   evaluation 
of antitumor efficacy of 5-fluorouracil (5-FU)-entrapped poly (D, L-lactic-co-glycolic acid) 
(PLGA) nanoparticles with dependence on the lactide/glycolide combination of PLGA. 
5-FU-loaded PLGA nanoparticles with two different monomer combinations, 50-50 and 90-10 
were   synthesized using a modified double emulsion method, and their biological evaluation 
was done in glioma (U87MG) and breast adenocarcinoma (MCF7) cell lines. 5-FU-entrapped 
PLGA 50-50 nanoparticles showed smaller size with a high encapsulation efficiency of 66%, 
which was equivalent to that of PLGA 90-10 nanoparticles. Physicochemical characterization 
of nanoparticles using differential scanning calorimetry and X-ray diffraction suggested the 
presence of 5-FU in molecular dispersion form. In vitro release studies showed the prolonged 
and sustained release of 5-FU from nanoparticles with both the PLGA combinations, where 
PLGA 50-50 nanoparticles showed faster release. Nanoparticles with PLGA 50-50 combination 
exhibited better cytotoxicity than free drug in a dose- and time-dependent manner against both the 
tumor cell lines. The enhanced efficiency of PLGA 50-50 nanoparticles to induce apoptosis was 
indicated by acridine orange/ethidium bromide staining. Cell cycle perturbations studied using 
flow cytometer showed better S-phase arrest by nanoparticles in comparison with free 5-FU. 
All the results indicate that PLGA 50-50 nanoparticles possess better antitumor efficacy than 
PLGA 90-10 nanoparticles and free 5-FU. Since, studies have shown that long-term exposure 
of ailing tissues to moderate drug concentrations is more favorable than regular administration 
of higher concentration of the drug; our results clearly indicate the potential of 5-FU-loaded 
PLGA nanoparticles with dependence on carrier combination as controlled release formulation 
to multiplex the therapeutic effect of cancer chemotherapy.
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Introduction
Cancer is one of the most challenging diseases to cure and the second leading cause of 
death in developed countries. Over the past few decades, it continues to be a worldwide 
health problem in spite of the rising number of nanoscaled technologies.1 Chemotherapy 
is the major therapeutic approach for the treatment of localized and metastasized 
cancers. Even though the development of both diagnostic and therapeutic tools is on 
the rise, nonselective distribution of drugs, enhanced drug toxicity, and undesirable 
side effects to normal tissues aggravate the challenges for chemotherapy. To prevail 
over this, carrier-mediated drug delivery offers a number of design opportunities for 
engineering the delivery of a particular drug, with enhanced therapeutic effect.2 It is 
proven that the entrapment of these anticancer agents in particles of nanometer and International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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micrometer range can control their release. Hence, in the area 
of chemotherapy, nanotechnology could be an alternative to 
improve the life expectancy of the cancer patients.
5-Fluorouracil (5-FU) a pyrimidine analog, is one of the 
broad spectrum anticancer drugs3–5 used in the treatment of 
malignancies like glioblastoma6 and breast cancer.7 Since 
5-FU interferes with DNA synthesis, it principally acts as 
a thymidylate synthase inhibitor.8,9 However, short half-life, 
wide distribution, and various side effects10–12 limit its medical 
applicability. To overcome the above mentioned limitations, 
an ample number of studies has been carried out on sustained 
drug delivery systems for 5-FU13–15 using polymers like poly 
(D, L-lactic-co-glycolic acid) (PLGA). PLGA, which is a 
US Food and Drug Administration-approved polymer, has 
  successfully been used as a carrier for drug delivery applica-
tions for a wide range of drugs, including 5-FU, for more than 
a decade now.16 One of the advantages of this polymer is that 
by regulating the lactide to glycolide ratio the degradation 
rate can be regulated.17,18 5-FU-loaded PLGA microspheres 
have been developed and studied for stereotactic intracerebral 
implantation in C6 glioma bearing rats with very promising 
results as far as survival, welfare, and future applications 
were forecast.19–21 Although 5-FU-loaded microparticles are 
envisaged as having great potential for drug delivery, their 
suitability for directing the drug to the tissues or cells via 
systemic circulation or mucous membrane remain hindered 
due to their large size. On the contrary, nanoscaled particles 
are capable of cellular internalization along with   permeation 
of connective tissues without blocking the capillaries. 
  Furthermore, due to leaky endothelial tissues that surround 
the tumor, these nanoparticles can pass through the vascula-
ture and accumulate in the solid tumors. Studies have shown 
that nanoparticles carrying anticancer agents show prolonged 
drug retention in the tumors, which diminishes tumor 
growth and thereby increases the life-span of tumor-bearing 
animals.22–24 Although studies are in progress to increase the 
bioavailability of 5-FU with nanoparticle carrier systems,25,26 
data showing biological efficacy of PLGA nanoparticles as 
a carrier for 5-FU have hardly been reported. Moreover, 
dependence of these nanoparticles on the combination of 
PLGA used has not been investigated so far.
The main aim of this work was to develop a PLGA-
based nanoparticle delivery system for 5-FU with two 
different monomeric combinations and to examine the 
effect of   lactide to glycolide ratio on their drug release 
and   cytotoxicity. 5-FU-entrapped PLGA nanoparticles, 
using PLGA 50-50 and 90-10, were prepared using the 
double emulsion method. These nanoparticles were further 
  characterized for their size, morphology, and charge using a 
particle size analyzer and transmission electron microscope 
(TEM). The thermal   behavior was studied using differential 
scanning calorimetry (DSC) and X-ray diffraction (XRD). 
In vitro drug release studies were performed to compare the 
release rate of 5-FU from the two polymeric combinations. 
For biological evaluation, glioblastoma (U87MG) and breast 
cancer (MCF7) cell lines were selected. The cellular uptake 
of these nanoparticles was done with a fluorescent dye 
using confocal microscopy. Controlled release of the drug 
from the nanoparticles and its antitumoral efficacy when 
compared with free 5-FU was analyzed using MTT (3-[4, 
5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bro-
mide) assay followed by acridine orange/ethidium bromide 
(AO/EB) staining in both the cell lines. The perturbations 
in cell cycle on treatment with 5-FU nanoformulations were 
analyzed by flow cytometer.
Materials and methods
Materials
PLGA polymer with co-polymerization ratios 50-50 and 
90-10 (lactic/glycolic) Mw 10–75 kDa, Pluronic® F-68, 
  rhodamine, 5-FU, MTT, Dulbecco’s modified Eagle’s 
medium (DMEM), trypsin-ethylenediaminetetraacetic acid 
(EDTA) and 4′,6-diamidino-2-phenylindole (DAPI) were 
purchased from Sigma-Aldrich (Steinheim, Germany), and 
fetal bovine serum (FBS) from Gibco (Life Technologies 
AG, Basel, Switzerland). All organic solvents were of high 
performance liquid chromatography grade.
Preparation of 5-FU-loaded PLgA 
polymer nanoparticles
5-FU-loaded PLGA nanoparticles with both the copolymeric 
ratios were prepared by the double emulsion (w/o/w) method. 
Briefly, 5-FU dissolved in water (1% w/v) was added to 
PLGA dissolved in dichloromethane (2% w/v) by vortexing 
to form the primary emulsion (w/o). This emulsion was then 
mixed with the aqueous phase (30 mL) containing Pluronic 
F-68 (1% v/v) as the surfactant to form the secondary emul-
sion (w/o/w). This emulsion was further disrupted into fine 
droplets by sonication at 130 W and 20 kHz power supply for 
2 minutes, and the organic solvent was evaporated completely 
by stirring the emulsion overnight. The nanoparticles were 
washed three times in distilled water by ultracentrifugation 
at 40,000 rpm (Optima™-100 K Ultracentrifuge, Beckman 
Coulter Inc, Brea, CA) at 4°C for 1 hour. The nanopar-
ticle suspension was   lyophilized (VirTis®, AdVantage, 
  Warminster, PA) at a condenser temperature of –55°C and International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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pressure of 720 mTorr with 5% (w/v) sucrose as a cryopro-
tectant to obtain the dry powder.
characterization of nanoparticles
Particle size and size distribution
The images of 5-FU-entrapped PLGA nanoparticles were 
taken using a JEM-1011 TEM (JEOL, Tokyo, Japan). For 
TEM, the samples of the nanoparticle suspension in Milli-Q® 
(Millipore Corporation, Billerica, MA) water at 25°C were 
dropped onto formvar-coated grids, and measurements 
were taken only after the samples were completely dried. 
The size distribution and zeta potential of these nanoparticles 
were analyzed using a Delsa™ Nano particle size analyzer 
(  Beckman Coulter, Inc).
Determination of drug encapsulation efficiency
The amount of 5-FU entrapped in the nanoparticles was 
determined by the separation of 5-FU-loaded nanoparticles 
from the suspension containing free 5-FU by   centrifugation. 
The suspension obtained after solvent evaporation was 
centrifuged, and the amount of free 5-FU in the supernatant 
was determined using an ultraviolet (UV) spectrophotometer 
(Perkin Elmer, Waltham, MA) at a wavelength of 267 nm. The 
concentration of free drug in the supernatant was obtained by 
comparing the absorption of the supernatant to the standard 
curve relating absorption and 5-FU concentration. The amount 
of drug entrapped into nanoparticles was calculated as the 
  difference between the drug used for formulation and the 
amount of drug in the supernatant and was expressed as encap-
sulation efficiency. The yield of nanoparticles was calculated 
as the ratio of the amount of nanoparticles recovered to the 
total amount of polymer and 5-FU used in formulation.
Dsc analysis
DSC thermograms of free 5-FU, empty nanoparticles, and 
5-FU-loaded PLGA nanoparticles were compared to analyze 
the physicochemical behavior of nanoparticles. DSC ther-
mograms were obtained using an automatic thermal analyzer 
system (Pyres 6 DSC, Perkin-Elmer). Samples were crimped 
in standard aluminum pans and heated from 20°C to 300°C 
at a heating rate of 15°C/minute under constant purging of 
N2 at 20 mL/minute. An empty pan, sealed in the same way 
as the sample, was used as a reference.
XrD
The crystalline nature of free 5-FU and 5-FU nanopar-
ticle formulations was compared by powder XRD patterns 
acquired at room temperature on an X-ray diffractometer 
(X’pert PRO, PANalytical, Lelyweg, the Netherlands) using 
Cu Kα radiation 5°C–60°C in continuous mode with a step 
size of 0.02° 2θ and step time of 5 seconds.
In vitro drug-release studies
To analyze the dependence of 5-FU release from PLGA 
combination, in vitro release studies were conducted. 
5-FU-loaded PLGA nanoparticles (50 mg) were dispersed 
in 50 mL of phosphate buffered saline (PBS) (pH 7.4) and 
incubated at 37°C under continuous shaking of 60 rpm. 
At predetermined intervals, 1 mL of release medium was 
  collected and replaced with fresh PBS to maintain sink condi-
tions. The newly collected release media was centrifuged, and 
the amount of 5-FU released was determined by UV spectro-
photometer at 267 nm. Using a standard curve for 5-FU, the 
cumulative amount of 5-FU released was evaluated.
cells and cell culture
U87MG glioma cells and MCF7 breast adenocarcinoma cells 
were cultured in DMEM supplemented with 10% FBS at 37°C 
under a humidified atmosphere containing 5% carbon dioxide. 
Until reaching 70% confluence in tissue culture flasks, the cells 
were trypsinized with buffered saline solution   containing 0.25% 
trypsin and 0.03% EDTA. After that, the cells were plated to 
culture plate as desired and allowed to attach for 24 hours. The 
dispersed nanoparticle suspensions in cell   culture medium were 
then diluted to specific concentrations and immediately added 
into the cells. After incubation for   predetermined durations, 
the cells were subsequently analyzed for the cellular uptake, 
viability, and morphological changes.
cellular uptake studies
Since 5-FU is a nonfluorescent drug, rhodamine-entrapped 
PLGA nanoparticles using both the combinations were 
prepared in order to study the cellular uptake. U87MG 
glioma cells and MCF7 breast adenocarcinoma cells were 
grown at a density of 5 × 103 cells/well in the same way as 
described above into 12-well plates containing sterile glass 
coverslips. The cells were incubated with 10 µmol/L of 
rhodamine-entrapped nanoparticles at 37°C for 2 hours and 
counterstained with DAPI. The cells were then washed twice 
with PBS to remove nanoparticles not taken up by the cells, 
fixed with 4% paraformaldehyde for 8 minutes, and again 
washed twice with PBS. Cells were mounted using glycerol, 
and the intracellular rhodamine fluorescence in the cells 
was examined under a confocal laser scanning microscope 
(TCS SP2; Leica Microsystems, Wetzlar, Germany) at a 
magnification of 60× and scan speed of 400 Hz.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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cytotoxicity assay
MTT reduction assay was performed to assess cell viability. 
Briefly, cells were seeded (5 × 103 cells/well) in a 96-well 
culture plate and incubated for 24 hours. Cells were given 
treatment with formulations of 5-FU (10–150 µM) for 24, 48, 
and 72 hours. Thereafter, MTT at a concentration of 5 mg/mL 
in PBS (pH 7.4) was added to each well (10% v/v), and the 
cells were further incubated for 4 hours at 37°C. After remov-
ing the unreacted medium, the blue crystals were dissolved in 
100 µL isopropyl alcohol, and optical density was measured 
at 570 nm. Cell viability (%) related to control wells contain-
ing cell culture medium without treatment was calculated by 
[A]test/[A]control × 100, where [A]test is the absorbance of the test 
sample and [A]control is the absorbance of the control sample. 
Six replicates were prepared for each sample.
AO/eB assay
AO/EB assay is reported to be a reliable method for the 
  quantification of apoptosis.27,28 Thus, for fluorescence 
cytochemical study, cells were seeded in a 35 mm culture dish 
and 5-FU treatment (100 µM) was given for 24 hours. Medium 
was removed, and the cells were washed with PBS. The cells 
were then given a combined staining of AO (50 mg/mL) and 
EB (5 mg/mL) for 5 minutes at room temperature and exam-
ined by an inverted fluorescence microscope (DMI 4000B; 
Leica Microsystems) at a magnification of 20×.
cell-cycle analysis
For flow cytometric analysis, 106 cells were seeded in 60-mm 
culture dishes. 5-FU treatment (50 µM) was given for 24 hours, 
and the cells were harvested and fixed with 70% ethanol for 
1 hour. The fixed cells were then given RNase A (100 mg/mL) 
treatment for 1 hour followed by incubation with propidium 
iodide (10 mg/mL), in the dark, for 15 minutes. Finally, DNA 
content of the cells was analyzed using FACSAria™ I special 
order system (BD Biosciences, San Jose, CA).
statistical analysis
All the measurements were done in triplicate, and the results 
were expressed as arithmetic mean ± standard error of the 
mean.
Results
characteristic parameters of 
nanoparticles are independent of lactide/
glycolide ratio of PLgA
5-FU nanoparticles having PLGA as a carrier were successfully 
prepared in the nanometer range using the double emulsion 
(w/o/w) method. 5-FU-entrapped PLGA nanoparticles showed 
an average size of 150 nm and 190 nm with 50-50 and 90-10 
combination (Figure 1). Nanoparticles with both the combina-
tions were spherical, with a narrow size distribution and low 
polydispersity index (Figure 2). A good yield of nanoparticles 
with similar encapsulation efficiency in the range of 66% was 
obtained for both the combinations. These results indicate the 
independence of size, polydispersity, and encapsulation of 
nanoparticles of the lactide to glycolide ratio of PLGA. Also, 
compared with blank PLGA nanoparticles, no significant 
change in size, polydispersity, and surface charge was seen on 
entrapping the nanoparticles with drug (Table 1).
To assess the thermal behavior of the nanoparticles, DSC 
was done on free 5-FU, blank PLGA nanoparticles, and 5-FU-
entrapped PLGA nanoparticles. As shown in Figure 3, pure 
5-FU showed the presence of an endothermic peak at 280.1°C, 
whereas both vacant and drug-entrapped nanoparticles showed 
a peak at 50°C. The peak near 280°C represents the melting of 
5-FU, whereas in the case of the empty and the 5-FU-loaded 
nanoparticles, the peak around 50°C (glass   transition tem-
perature [Tg] of PLGA) are   typical of the   polymer. The DSC 
thermograms suggested the   presence of 5-FU in molecular 
dispersion form inside the polymer matrix.
To study the effect of 5-FU entrapment on its   crystalline 
behavior, XRD patterns of free 5-FU, blank PLGA 50-50, and 
5-FU-loaded PLGA 50-50 nanoparticles were obtained and 
compared. For the free 5-FU, the diffractograms exhibited 
an intense peak at the 2θ values near 28 due to its crystalline 
nature, while vacant as well as drug-entrapped nanoparticle 
formulations showed no characteristic peak of 5-FU, support-
ing DSC results of the presence of drug in solid dispersion 
form (Figure 4).
5-FU-entrapped PLgA 50-50 
nanoparticles showed faster release
One of the major aims of this study was to analyze the effect 
of change in the lactide/glycolide ratio on the release pattern   
AB
0.2 µm 0.5 µm
Figure 1 Transmission electron microscopy images of 5-FU-entrapped PLgA 50-50 
(A) and PLgA 90-10 nanoparticles (B).
Abbreviations: FU, 5-fluorouracil; PLGA, poly (D, L-lactic-co-glycolic acid).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1689
5-fluorouracil nanoparticles
of 5-FU from PLGA nanoparticles. It was seen that nanopar-
ticles with both the combinations continued to release 5-FU 
for a period of 1 week (Figure 5). On comparing the release 
pattern of 5-FU from PLGA 50-50 and 90-10 nanoparticles, it 
was observed that within 48 hours 25% 5-FU was released from 
PLGA 50-50 nanoparticles compared with 20% of 5-FU from 
PLGA 90-10 nanoparticles. At the end of 1 week, only 65% of 
the drug was released in the case of 90:10 nanoparticles com-
pared with the release of 85% 5-FU from 50-50 nanoparticles. 
This variation in the release rate was because of the variation 
in the lactide/glycolide ratio, which alters the degradability of 
PLGA. Since the 50-50 combination contains a higher percent-
age of the hydrophilic block polyglycolide compared with 90-10, 
which contains a major percentage of hydrophobic polylactide, it 
shows faster degradability resulting in a faster release of 5-FU.
Internalization of 5-FU nanoparticles is 
independent of the lactide/glycolide ratio 
of PLgA
Since 5-FU is a nonfluorescent drug, cellular uptake of these 
nanoparticles in U87MG and MCF7 cell lines was studied 
using rhodamine dye. Nanoparticles were internalized as 
early as 2 hours after incubation, which was evident from the 
red fluorescence of rhodamine in the cell cytoplasm. The cel-
lular uptake and subsequent localization of rhodamine-PLGA 
nanoparticles in U87MG and MCF7 cells are represented in 
Figures 6 and 7. It was observed that PLGA nanoparticles 
were efficiently taken up by both the cell lines, irrespective 
of the lactide/glycolide ratio of PLGA used as a carrier.
Loss of viability by 5-FU nanoparticles is 
monomeric concentration dependent
We further analyzed the cytotoxic effect of 5-FU nanopar-
ticles, and polymer nanoparticles with no drug showing 
more cell viability, proving biocompatibility of PLGA. On 
the contrary, 5-FU-entrapped nanoparticles exhibited higher 
cytotoxicity than that of free 5-FU over a range of experimen-
tal concentrations against two tumor cell lines. When U87MG 
cells were exposed to nanoparticles for 24 hours, viability 
of 72% for PLGA 50-50 and 74.6% for 90-10 nanoparticles 
at a concentration of 25 µmol/L, compared with free 5-FU 
(78.5%), was observed. Further incubation for 48 hours 
showed a decrease in cell viability in a concentration-
dependent manner, with nanoparticles maintaining higher 
cytotoxicity. At the end of 3 days, compared with 54.2% cell 
viability for free 5-FU, a cell viability of 48.3% and 50.9% 
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Figure 2 Polydispersity graphs of 5-FU-entrapped PLgA 50-50 (A) and PLgA 90-10 nanoparticles (B).
Abbreviations: FU, 5-fluorouracil; PLGA, poly (D, L-lactic-co-glycolic acid).
Table 1 characterization of nanoparticles
Sample Encapsulation 
Efficiency % 
Yield % Mean Diameter  
(nm)
Polydispersity 
Index
Zeta 
Potential
Blank PLgA nanoparticles - 86.4 ± 2.3 135.4 ± 5.6 0.031 ± 0.013 -24.5 ± 4.3
5-FU PLgA 50-50 nanoparticles 66.65 ± 0.90 88.6 ± 1.78 150.55 ± 6.01 0.064 ± 0.029 -18.3 ± 6.1
5-FU PLgA 90-10 nanoparticles 65.53 ± 0.73 88.4 ± 2.13 190.30 ± 7.35 0.035 ± 0.016 -21.3 ± 3.5
Abbreviations: FU, 5-fluorouracil; PLGA, poly (D, L-lactic-co-glycolic acid).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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was seen for 5-FU PLGA 50-50 and 90-10 nanoparticles at 
25 µmol/L, respectively (Figure 8).
Similarly, our results with MCF7 breast cancer cells also 
showed that PLGA nanoparticles containing 5-FU exhib-
ited better toxicity than that of free 5-FU. Incubation for 
24 hours with 5-FU-entrapped nanoparticles showed higher 
  cytotoxicity (20%–21%) when compared with cell death 
caused by 10 µmol/L of free drug (10%). However, 72 hours 
treatment for 50-50 nanoparticles showed highest cytotoxic-
ity (61.5%) compared with free 5-FU (48.8%) and 90-10 
nanoparticles (50.3%) (Figure 9). Interestingly, our study 
using PLGA 90-10 nanoparticles showed higher cell viability 
than 50-50 nanoparticles; this may be due to its higher lactide 
content, contributing to slower release as our results depict. 
Our results thereby justify that these nanoparticles may have 
an enhanced potential as a chemotherapeutic compared with 
free drug.
5-FU nanoparticles induced apoptosis  
in tumor cell lines
To further characterize the cytotoxic effect of 5-FU nanopar-
ticles, cells were incubated with 100 µmol/L of 5-FU formula-
tions for 24 hours, and a fluorescence cytochemical study was 
done. Cytochemical staining using AO and EB revealed char-
acteristic chromatin condensation. EB was selectively taken up 
by apoptotic cells and stained the condensed nuclei, whereas the 
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(B), and 5-FU entrapped PLgA 50-50 nanoparticles (C).
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Rhodamine PLGA 50-50 NPs
Rhodamine PLGA 90-10 NPs
DAPI Merged
Merged DAPI
Figure 6 confocal images of U87Mg cells after 2 hours incubation with rhodamine-entrapped PLgA NPs.
Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; NP, nanoparticle; PLGA, poly (D, L-lactic-co-glycolic acid).
Rhodamine PLGA 50-50 NPs DAPI Merged
Rhodamine PLGA 90-10 NPs DAPI Merged
Figure 7 confocal images of McF7 cells after 2 hours incubation with rhodamine-entrapped PLgA NPs.
Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; NP, nanoparticle; PLGA, poly (D, L-lactic-co-glycolic acid).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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control cells had only taken up AO (97%). 5-FU PLGA 50-50 
nanoparticles showed less viability, with 50% and 23% death 
in U87MG and MCF7 cells, respectively. On the other hand, 
45% and 7% of U87MG and MCF7 cells showed condensed 
chromatin on free 5-FU treatment   (Figures 10 and 11).
5-FU in nanoform induced significant  
s-phase arrest in the cell division cycle
Nuclear condensation results indicated that the cells may 
have undergone DNA damage. Therefore, we performed cell-
cycle analysis to identify whether treated cells underwent a 
synthetic phase arrest. We observed that cells passed through 
the mitotic division but were arrested at the S-phase, and 
therefore determined the drug was acting as a DNA synthase 
inhibitor. 5-FU PLGA nanoparticles caused higher S-phase 
arrest (27.2% and 24.1%) in U87MG cells. In MCF7 cells 
also, a significant increase in the S phase was seen. Here 
also, PLGA 50-50 nanoparticles induced considerably higher 
(42.0%) arrest compared with 90-10 nanoparticles (30.5%) 
and free drug (20.6%), respectively (Figure 12).
Discussion
Chemotherapy is one of the treatment methods for can-
cer, which is one of the leading causes of death in the 
world. But side effects associated with overdosing and 
low   therapeutic index restrict the use of chemotherapeutic 
agents. 5-FU, sold under the brand names Adrucil® and 
Efudex®, is an anticancer drug used in the treatment of a 
variety of   cancers. But side effects such as dermatitis, cardiac 
  toxicity, and damage of the central nervous system limit its 
applications.29   Existing reports have shown the potential of 
controlled release systems30,31 using polymers to avoid the 
side effects caused due to overdosing and repeated infusion 
of drug. Although PLGA-based 5-FU-loaded microspheres 
and implant   systems31–33 have shown promising results 
compared with free drug, the literature still lacks studies 
evaluating the efficiency of 5-FU particles at the nano level. 
Nanoparticles possess the ability to permeabilize the cells 
more efficiently than microspheres due to their smaller size, 
which facilitates administration of large quantities of drug 
to give better efficacy.
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Figure 8 cell viability of U87Mg cells treated with 5-FU-entrapped PLgA 50-50 and 90-10 NPs compared with free 5-FU (mean ± standard deviation; n = 6).
Abbreviations: conc, concentration; FU, 5-fluorouracil; NP, nanoparticle; PLGA, poly (D, L-lactic-co-glycolic acid).
Figure  9  cell  viability  of  McF7  cells  treated  with  5-FU-entrapped  PLgA  50-50  and  90-10  NPs  compared  with  free  5-FU  (mean  ±  standard  deviation;  n  =  6). 
Abbreviations: Conc, concentration; FU, 5-fluorouracil; NP, nanoparticle; PLGA, poly (D, L-lactic-co-glycolic acid).
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In the present work, 5-FU PLGA nanoparticles were 
prepared using a modified solvent evaporation method,34 and 
a comparative study was done using two different lactide/
glycolide combinations, 50-50 and 90-10. The nanoparticles 
were successfully prepared with considerably good encap-
sulation efficiency25 and high yield. From the TEM images 
(Figure 1) and size distribution graph (Figure 2), it was shown 
that particles with spherical size and uniform size distribution 
were obtained. Compared with blank PLGA nanoparticles, 
entrapment of 5-FU caused a slight increase in the size and 
zeta potential, which might be due to the presence of free 
drug on the particle surface. It was observed that variation 
in the lactide to glycolide ratio of the nanoparticles did not 
show any significant variation in the drug encapsulation, 
size, yield, and zeta potential, both combinations showing 
almost similar parameters (Table 1). Absence of drug peak 
in the DSC results (Figure 3) suggested the presence of 5-FU 
in molecular dispersion form inside the polymer matrix.35 
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Figure 10 Fluorescence images of U87MG cells stained with acridine orange/ethidium bromide followed by quantification of apoptosis based on morphology changes. 
Abbreviations: FU, 5-fluorouracil; NP, nanoparticle; PLGA, poly (D, L-lactic-co-glycolic acid).
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Figure 11 Fluorescence images of MCF7 cells stained with acridine orange/ethidium bromide followed by quantification of apoptosis based on morphology changes. 
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Figure 12 cell-cycle analysis of U87Mg (A) and McF7 (B) cells on treatment with different 5-FU formulations.
Abbreviations: FU, 5-fluorouracil; NP, nanoparticle; PLGA, poly (D, L-lactic-co-glycolic acid).
The thermograms demonstrated that there is no interaction 
between the drug and the polymer, 5-FU, maintaining its 
crystalline nature. This data is important because the presence 
of drug in molecular dispersion form helps in its sustained 
release.36 This was further confirmed by the absence of   
a 5-FU peak in the X-ray diffractograms of the nanopar-
ticle formulation (Figure 4). To analyze the dependence of 
PLGA combination on drug release, in vitro release studies 
were conducted. In agreement with previous reports,18,37 
PLGA 50-50 nanoparticles showed faster in vitro release of 
5-FU compared with PLGA 90-10 (Figure 5), which might be 
due to the presence of higher glycolide content in the 50-50 
combination that accounts for its faster degradability.
Since 5-FU is reported to be effective in the treatment 
of brain cancers32,38 and breast cancer,39,40 glioblastoma 
(U87MG) and breast adenocarcinoma (MCF7) cell lines were International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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selected for the biological evaluation of these   nanoparticles. 
Since 5-FU is a nonfluorescent drug, the intracellular uptake 
of nanoparticles was shown by encapsulating rhodamine 
dye in PLGA nanoparticles using both the combinations. 
For contrast to the red color of rhodamine, nuclei were 
stained with DAPI which stains blue.   Incubation of the cells 
with 10 µmol/L of nanoparticles for just 2 hours showed 
considerable red intracellular fluorescence in both the cell 
lines (Figures 6 and 7). Also, both the PLGA combinations 
showed efficient uptake, indicating the independence of 
cellular uptake from lactide/glycolide ratio of PLGA. Cell 
viability studies conducted for three different time dura-
tions showed that nanoparticles induced a clear dose as 
well as time-dependent growth inhibition in both the cell 
lines   (Figures 8 and 9), with PLGA 50-50 nanoparticles 
showing the highest cytotoxicity. Among various methods 
used to detect apoptosis, chromatin condensation and 
nuclear fragmentation remain the hallmarks of apoptotic 
cells, since it allows distinguishing viable, early or late 
apoptotic and necrotic cells. In AO/EB double staining, 
AO permeates all cells and makes the nuclei appear green, 
whereas EB stains the nucleus red only when cytoplasmic 
membrane integrity is lost. Thus, live cells show a normal 
green nucleus; early apoptotic cells a bright green nucleus 
with condensed or fragmented chromatin; late apoptotic 
cells show condensed and fragmented orange   chromatin; 
and cells that have died from direct necrosis show a 
structurally normal orange nucleus.27,28 Our results of AO/
EB staining also exhibited a higher number of apoptotic 
cells on treatment with PLGA 50-50 nanoformulation 
 ( Figures 10 and 11) compared with free 5-FU and PLGA 
90-10 nanoparticles. Since 5-FU interferes with DNA 
synthesis,41 the alterations in cell cycle progression on 
treatment with 5-FU formulations were studied using 
fluorescence-activated cell sorting (FACS) analysis. In the 
case of the U87MG cell line, it was seen that the ratio of 
cells arrested in the S phase was higher on nanoparticle 
treatment (27.2% and 24.1%) compared with the arrest 
caused by the same concentration of free drug (22.5%). 
Similarly, MCF7 cells showed a significant S phase arrest 
on treatment with nanoparticles (42% and 30.5%), which 
was considerably higher than the arrest caused by free 5-FU 
(20.6%) (Figure 12). This explains the better efficiency of 
5-FU entrapped PLGA nanoparticles compared with free 
5-FU. Here also, in agreement with our previous results, 
PLGA 50-50 nanoparticles induced the highest cell arrest. 
Since blank PLGA nanoparticles are nontoxic, their data 
for AO/EB staining and FACS is not shown. Analysis of 
the results of cytotoxicity studies followed by AO/EB assay 
and FACS depict that PLGA 50-50 nanoparticles showed 
better potency than 90-10 nanoparticles in both the cell 
lines, indicating the variation in cytotoxicity with the lac-
tide/glycolide combination of PLGA used. Although the 
potential of 5-FU-loaded PLGA microspheres has already 
been reported,38,42–44 limitations associated with their size 
restrict their efficacy in cancer therapy. Since data from the 
literature show that continuous infusion of low-doses is an 
excellent regimen for inducing cell death more effectively 
than a single high-dose exposure,45 it supports the idea that 
nanoparticle-based sustained-release formulations could 
be very promising in improving the efficacy of therapeutic 
agent. Also, we report for the first time the dependence of 
lactide/glycolide ratio on the anticancer activity of drug-
entrapped PLGA nanoparticles. Since leaky vasculature 
and poor lymphatic drainage present in most tumors46 
facilitates the entry of nanosized particles,47 our results 
support the rationale behind using 5-FU   nanoformulations 
in medical cancer therapeutics.
Conclusion
5-FU-loaded PLGA nanoparticles were prepared to over-
come the side effects associated with overdosing and size-
associated limitations of microspheres in chemotherapy. 
In a novel study, the dependence of monomeric ratio of 
the carrier PLGA on potency was evaluated by preparing 
5-FU nanoparticles with two different monomeric ratios 
of PLGA, 50-50 and 90-10. Particles with the two ratios 
mainly differed in their drug release kinetics, with PLGA 
50-50 showing faster release. A cytotoxicity study followed 
by AO/EB assay and FACS analysis clearly demonstrated 
the superior efficiency of these nanoparticles to induce apop-
tosis in glioma (U87MG) and breast cancer (MCF7) cells 
compared with free drug. Notably, variation in the lactide/
glycolide combination of PLGA varied the extent of drug 
release, which altered the ability of nanoparticles to induce 
cell death. This resulted in higher efficacy of PLGA 50-50 
nanoparticles to cause apoptosis compared with 90-10. Thus, 
our results clearly demonstrate that 5-FU-entrapped PLGA 
nanoparticles can open new frontiers for clinical therapeutics 
in cancer chemotherapy.
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